Our CEO, Jesper J. Lange will present a business update at the 24th Bio€quity Europe in San Sebastián, Spain from 11:15-11:27 CEST on 14th May during the ‘Autoimmune, Inflammation and Fibrosis’ session (Room 9).
We will be delving deeper into MC2 Therapeutics’ novel treatment paradigms, incl. our Phase 2 stage first-in-class oral drug candidate, MC2-32, an HSP90 inhibitor targeting pathways involved in numerous Immunology and Inflammation diseases.
Please reach out to EA to the CEO, Lonni Goltermann at log@mc2therapeutics.com if you would like to arrange a meeting during the event.
BACK
